AU2017275769B2 - Diet controlled expression of a nucleic acid encoding Cas9 nuclease and uses thereof - Google Patents

Diet controlled expression of a nucleic acid encoding Cas9 nuclease and uses thereof Download PDF

Info

Publication number
AU2017275769B2
AU2017275769B2 AU2017275769A AU2017275769A AU2017275769B2 AU 2017275769 B2 AU2017275769 B2 AU 2017275769B2 AU 2017275769 A AU2017275769 A AU 2017275769A AU 2017275769 A AU2017275769 A AU 2017275769A AU 2017275769 B2 AU2017275769 B2 AU 2017275769B2
Authority
AU
Australia
Prior art keywords
nucleic acid
expression
cas9
disease
aare
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017275769A
Other languages
English (en)
Other versions
AU2017275769A1 (en
Inventor
Jacques Mallet
Philippe Ravassard
Ché SERGUERA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Sorbonne Universite
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Institut du Cerveau et de La Moelle Epiniere ICM
Original Assignee
Centre National de la Recherche Scientifique CNRS
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Sorbonne Universite
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Institut du Cerveau et de La Moelle Epiniere ICM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Assistance Publique Hopitaux de Paris APHP, Institut National de la Sante et de la Recherche Medicale INSERM, Sorbonne Universite, Commissariat a lEnergie Atomique et aux Energies Alternatives CEA, Institut du Cerveau et de La Moelle Epiniere ICM filed Critical Centre National de la Recherche Scientifique CNRS
Publication of AU2017275769A1 publication Critical patent/AU2017275769A1/en
Application granted granted Critical
Publication of AU2017275769B2 publication Critical patent/AU2017275769B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
AU2017275769A 2016-06-03 2017-06-02 Diet controlled expression of a nucleic acid encoding Cas9 nuclease and uses thereof Active AU2017275769B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPEP16172964 2016-06-03
EP16172964 2016-06-03
PCT/EP2017/063549 WO2017207797A1 (en) 2016-06-03 2017-06-02 Diet controlled expression of a nucleic acid encoding cas9 nuclease and uses thereof

Publications (2)

Publication Number Publication Date
AU2017275769A1 AU2017275769A1 (en) 2018-12-20
AU2017275769B2 true AU2017275769B2 (en) 2023-04-13

Family

ID=56148119

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017275769A Active AU2017275769B2 (en) 2016-06-03 2017-06-02 Diet controlled expression of a nucleic acid encoding Cas9 nuclease and uses thereof

Country Status (11)

Country Link
US (2) US20190185832A1 (cg-RX-API-DMAC7.html)
JP (2) JP7436145B2 (cg-RX-API-DMAC7.html)
KR (1) KR102317622B1 (cg-RX-API-DMAC7.html)
CN (2) CN116064534A (cg-RX-API-DMAC7.html)
AU (1) AU2017275769B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018074930A2 (cg-RX-API-DMAC7.html)
CA (1) CA3025591A1 (cg-RX-API-DMAC7.html)
IL (1) IL263291B2 (cg-RX-API-DMAC7.html)
RU (1) RU2771383C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201810772XA (cg-RX-API-DMAC7.html)
WO (1) WO2017207797A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113227152A (zh) * 2018-08-01 2021-08-06 科罗拉多大学评议会法人团体 用于大分子递送和基因组修饰的可编程设计因子治疗性促融合分泌性g型核外颗粒体囊泡
CN112442528B (zh) * 2019-08-30 2022-08-12 深圳华大基因股份有限公司 Loxhd1基因突变体及其应用
CN114058689B (zh) * 2020-07-30 2024-08-20 南京市妇幼保健院 一种基因突变检测试剂盒及其应用
AU2023304674A1 (en) * 2022-07-05 2025-01-16 Centre Hospitalier Universitaire De Clermont-Fd Controlled expression of a transgene in human t or nk cells for use in cellular immunotherapy
WO2024100176A1 (en) * 2022-11-10 2024-05-16 Nutritheragene Controlled gene therapy of ocular diseases
CN116732043B (zh) * 2023-08-10 2023-10-17 四川省医学科学院·四川省人民医院 一种突变基因及其白内障筛查的用途与白内障筛查试剂盒

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013068096A1 (fr) * 2011-11-08 2013-05-16 Institut National De La Recherche Agronomique (Inra) Cassette d'expression inductible et ses utilisations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3138910T (lt) * 2012-12-06 2017-11-10 Sigma-Aldrich Co. Llc Crispr pagrįstas genomo modifikavimas ir reguliavimas
US20150098954A1 (en) * 2013-10-08 2015-04-09 Elwha Llc Compositions and Methods Related to CRISPR Targeting
AU2014361781B2 (en) * 2013-12-12 2021-04-01 Massachusetts Institute Of Technology Delivery, use and therapeutic applications of the CRISPR -Cas systems and compositions for genome editing
WO2015089465A1 (en) * 2013-12-12 2015-06-18 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013068096A1 (fr) * 2011-11-08 2013-05-16 Institut National De La Recherche Agronomique (Inra) Cassette d'expression inductible et ses utilisations

Also Published As

Publication number Publication date
CN116064534A (zh) 2023-05-05
KR102317622B1 (ko) 2021-10-26
CN109906271A (zh) 2019-06-18
BR112018074930A2 (pt) 2019-03-12
JP7436145B2 (ja) 2024-02-21
RU2018142174A3 (cg-RX-API-DMAC7.html) 2020-09-30
KR20190031230A (ko) 2019-03-25
IL263291B1 (en) 2023-03-01
US20230313161A1 (en) 2023-10-05
RU2771383C2 (ru) 2022-05-04
IL263291A (en) 2018-12-31
US20190185832A1 (en) 2019-06-20
JP2019517262A (ja) 2019-06-24
WO2017207797A1 (en) 2017-12-07
RU2018142174A (ru) 2020-07-10
IL263291B2 (en) 2023-07-01
JP2022133441A (ja) 2022-09-13
SG11201810772XA (en) 2018-12-28
CA3025591A1 (en) 2017-12-07
AU2017275769A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
AU2017275769B2 (en) Diet controlled expression of a nucleic acid encoding Cas9 nuclease and uses thereof
AU2016214301B2 (en) Primary hematopoietic cells genetically engineered by slow release of nucleic acids using nanoparticles
CA2304642C (en) Expression of endogenous genes by non-homologous recombination of a vector construct with cellular dna
CN110856724B (zh) 包含核酸及car修饰的免疫细胞的治疗剂及其应用
AU2017248259A1 (en) Chimeric antigen receptor T cell compositions
AU2017301609A1 (en) BCL11A homing endonuclease variants, compositions, and methods of use
CN107746845A (zh) 特异性靶向LAG‑3基因的sgRNA和特异性敲除LAG‑3基因的方法
KR20180113990A (ko) 가족성 고콜레스테롤혈증을 치료하기 위한 유전자 요법
JP7725514B2 (ja) 結節性硬化症の遺伝子治療
AU2020455080B2 (en) Vaginal gel preparation and preparation method therefor
KR20210005184A (ko) 유전자 치료 방법
US20240018542A1 (en) Co-packaging to mitigate intermolecular recombination
CN107760680B (zh) 特异性靶向TIM-3基因的sgRNA和特异性敲除TIM-3基因的方法
KR20210102247A (ko) Crispr 수퍼-리프레서에 의한 생체내 합성 면역조절
JP2022541788A (ja) Ｈｉｖ感染症を治療するための長寿命ｔ細胞
CN115704023A (zh) 靶向USH2A基因pre-mRNA的gRNA、递送系统和CRISPR-Cas系统
CN113667017A (zh) 一种可提高CRISPR/Cas9系统同源重组效率的方法和应用
CN115247181A (zh) 一种用于制备脱发模型猪的核移植供体细胞的试剂盒及其制备方法
RU2810116C1 (ru) Вагинальный гель и метод его изготовления
CN112272565A (zh) 使用慢病毒基因构建体的递送的体内基因疗法
US20240368632A1 (en) Cells modified by a cas12i polypeptide
CN109628487A (zh) 一种利用转基因猪唾液腺制备人神经生长因子的方法
CN115247180A (zh) 试剂盒及其在构建毛囊组织特异表达人源II型5α-还原酶基因的重组猪细胞中的应用
CN117677630A (zh) 用于治疗神经退行性疾病的颗粒体蛋白/上皮素模块及其组合
HK40024932A (en) Therapeutic agent comprising nucleic acid and car-modified immune cell and application thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)